Technology Behind
Technology Behind the Liposomal Tri-Active System
The Liposomal Tri-Active System encapsulates salicylic acid (SA), glycolic acid (GA), and lauric acid (LA) within a phospholipid-based carrier, forming a high-performance delivery platform designed for enhanced penetration, targeted localization, and sustained release.
Its bilayer structure fuses with skin lipids, facilitating direct transport of the actives into both the stratum corneum and follicular pathways. Once localized, salicylic acid is gradually released into the pores to alleviate inflammation and dissolve accumulated debris. Glycolic acid acts at the epidermal surface, gently loosening corneocyte cohesion to promote controlled exfoliation and skin renewal. Lauric acid integrates into bacterial membranes, disrupting Cutibacterium acnes integrity and delivering potent antimicrobial action.
This multi-mechanistic strategy addresses acne at its root causes—follicular blockage, inflammation, and microbial overgrowth—while the liposomal encapsulation system minimizes irritation and supports optimal skin tolerance.
Mechanism of Action
The Liposomal Tri-Active System optimizes acne-targeted therapy through enhanced skin penetration, localized delivery, and sustained release. Its phospholipid bilayer seamlessly integrates with skin lipids, facilitating efficient transport of encapsulated actives into deeper epidermal layers. Salicylic acid is gradually released into the pores, where it alleviates inflammation and clears follicular blockages. Glycolic acid acts at the stratum corneum, gently disrupting corneocyte cohesion to promote controlled exfoliation and epidermal renewal. Lauric acid, delivered via lipid fusion, disrupts Cutibacterium acnes cell membranes, providing potent antimicrobial action. This multi-targeted, nanotechnology-driven system ensures synergistic efficacy while minimizing irritation for improved skin clarity and tolerance.
Sustained Release
85.7% release over the study period, ensuring prolonged availability of actives.
Targeted Skin Deposition
Delivers 66% of actives into skin layers for enhanced local action.
Extended Retention
Provides up to 10× higher residence time than non-encapsulated actives, prolonging efficacy.
Pharmacokinetics
Liposomal Tri-Active Delivery Performance
- Liposomal encapsulation achieves sustained release of 85.73% over 6 hours, ensuring prolonged therapeutic activity.
- Delivers high skin retention of 65.96%, maintaining effective concentrations at the target site.
- Minimizes irritation by targeted dermal delivery and reduced systemic absorption.
- Encapsulation of salicylic, glycolic, and lauric acids prevents direct skin contact, reducing irritation compared to conventional formulations.
